

# ASX Release

EMVision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## ON TARGET FOR TRIAL TO COMMENCE Q4 CALENDAR 2019


**EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”)** a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to provide a product development update on the Company’s portable, cost-effective and non-invasive brain scanner, which will be used in the pilot clinical trial at the Princess Alexandra Hospital in Brisbane. In this trial, data will be collected from patients with diagnosed ischaemic and haemorrhagic stroke, with confirmatory CT and/or MRI images.

### Portable Brain Scanner – Completion of Design and Development Phase

Our project team continues to make excellent progress against our project plan and the Company has now completed the design and development requirements for our clinical units. The bill of materials (BOM) for these units has been released and all components have been received or are on order. The fabrication and assembly of our clinical units, which is expected to last approximately 6-8 weeks, has now commenced.

To support procurement, clinical unit fabrication and testing, EMVision has established a dedicated small-scale prototype facility in Sydney. This facility will allow internal verification testing to be conducted in parallel and in collaboration with key suppliers, the University of Queensland research team and clinicians, as we prepare to deliver two clinical units to the Princess Alexandra Hospital for our forthcoming clinical trial.

### CLINICAL DEVICE DEVELOPMENT PATHWAY



### PROJECT ROADMAP

**BRAIN SCANNER**  
Identify and monitor stroke  
and traumatic brain injury




Milestone	Timing	Status
ISO 13485 Certification	H1	✓
Successful Healthy Human Trials	H1	✓
Clinical trial protocol designed, clinical advisors appointed, and ethics clearance obtained	H1	✓
Successful hospital site evaluation	H1	✓
Clinical unit bill of materials (BOM) review, release and procurement	Q3	✓
Commence fabrication and assembly of clinical units (x2)	Q3	✓
Verification and testing of clinical trial units prior to hospital delivery	Q4	
Delivery of clinical trial units to hospital	Q4	
Clinical site initiation visit and training of site staff for trial commencement	Q4	

Calendar Year 2019

The development pathway for the Company's clinical units is illustrated above. The above indicative project timetable and below product pipeline roadmap is a guide of the Company's intentions at the date of this announcement only. The Company reserves the right to vary the timetable at its discretion, and further notes that the timings are subject to change due to circumstances outside of its control.

The achievement of the above project milestones is an important phase in the Company's product development and commercialisation strategy.



[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills  
Investor & Media Relations  
+61 468 385 208  
michael@spring-communications.com.au

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.9 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

## **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMvision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.